Intensity Therapeutics Inc. (NASDAQ:INTS) Stock Has Consensus Target Price of $7.00 According to Analysts

Shares of Intensity Therapeutics Inc. (NASDAQ:INTS) have received an average recommendation of “Moderate Buy” from the five ratings firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $7.00.

Several research firms have weighed in on INTS. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Intensity Therapeutics in a research report on Tuesday, July 21st. Citigroup reissued a “buy” rating on shares of Intensity Therapeutics in a research note on Tuesday, August 11th. Finally, HC Wainwright boosted their target price on shares of Intensity Therapeutics from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Tuesday, August 18th.

Intensity Therapeutics Stock Up 2.9%

NASDAQ:INTS opened at $3.55 on Wednesday. The stock has a 50-day simple moving average of $4.07 and a 200 day simple moving average of $4.54. Intensity Therapeutics has a 52-week low of $3.21 and a 52-week high of $43.50. The company has a market cap of $11.57 million, a PE ratio of -0.99 and a beta of 2.81. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.00 and a current ratio of 5.00.

Intensity Therapeutics (NASDAQ:INTS) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.24). On average, sell-side analysts expect that Intensity Therapeutics will post -2.64 EPS for the current fiscal year.

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to treat solid tumors and stimulate the body’s immune system. The company’s approach is based on its proprietary DfuseRx technology, which is intended to improve the delivery of anticancer agents into tumor cells while promoting an immune response against treated and potentially untreated tumors.

Its lead product candidate, INT230-6, is an investigational intratumoral therapy that combines the cancer-killing agents cisplatin and vinblastine with a formulation designed to facilitate their distribution within tumors.